Table 1. Patient clinical and characteristics.
| Characteristics | Number of subjects | Median progression-free survival (month) | P value |
|---|---|---|---|
| Age at ketoconazole therapy, median 71 years (range 50–83 years) | 0.213 | ||
| <71 years | 79 | 3.0 | |
| ≥71 years | 84 | 2.6 | |
| Clinical T stage | 0.239 | ||
| T2 | 66 | 3.0 | |
| T3–4 | 33 | 2.8 | |
| Unknown | 64 | 2.0 | |
| Metastasis site | 0.778 | ||
| Lymph nodes only | 10 | 3.0 | |
| Bone only | 132 | 2.7 | |
| Lymph nodes and bone | 16 | 2.6 | |
| Internal organ | 5 | 2.8 | |
| Biopsy Gleason score | 0.041 | ||
| 4–6 | 72 | 3.1 | |
| 7 | 70 | 1.9 | |
| 8–10 | 21 | 3.0 | |
| Nadir PSA | <0.001 | ||
| <0.2 ng ml−1 | 70 | 3.5 | |
| ≥0.2 ng ml−1 | 93 | 1.4 | |
| PSADT | 0.025 | ||
| <2.0 months | 62 | 1.9 | |
| ≥2.0 months | 101 | 3.0 | |
| Baseline PSA | 0.615 | ||
| <20 ng ml−1 | 76 | 2.8 | |
| ≥20 ng ml−1 | 87 | 2.6 | |
| Baseline testosterone | <0.001 | ||
| <0.1 ng ml−1 | 76 | 1.6 | |
| ≥0.1 ng ml−1 | 87 | 3.1 | |
| Baseline haemoglobin | 0.004 | ||
| Normal (≥120 g l−1) | 93 | 2.8 | |
| Less than normal | 70 | 1.9 | |
| Baseline alkaline phosphatase | 0.004 | ||
| Normal (≤130 IU l−1) | 66 | 3.0 | |
| Greater than normal | 97 | 1.9 | |
| Docetaxel chemotherapy | 0.517 | ||
| Yes | 11 | 2.0 | |
| No | 152 | 2.6 |
Abbreviations: PSA, prostate-specific antigen; PSADT, PSA doubling time.
The cutoffs for the nadir PSA and PSADT were based on the literature; the cutoffs for the baseline PSA and testosterone were based on the Youden index; the cutoffs for the baseline haemoglobin and alkaline phosphatase were the limiting value of the normal level.
The P value was calculated by the univariate Cox regression analysis.